前列腺癌的生物学行为和进展模式存在明显差异，目前对中危前列腺癌的治疗争论是研究热点。本课题组前期利用前列腺癌表达谱数据，根据中危前列腺癌Gleason评分从3分到4分的演变构建数学模型进行基因筛选，再带入外部预后数据进行矫正，建立了区分中危前列腺癌惰性/进展性的多基因模型。通过GO分析，发现该模型中基因组合与肿瘤增殖存在明确关联。据此我们提出假设，该多基因组合参与了前列腺癌侵袭性的演变。本课题拟进一步通过体外和体内实验证实该基因组合对前列腺癌侵袭性的作用，寻找关键基因和信号通路；建立可以指导治疗的多基因决策模型。本课题的实施有望进一步揭示前列腺癌的进展机制，建立指导前列腺癌个体化治疗的决策模型，为早期区别干预前列腺癌提供可能靶点，具有重要的科学意义和临床应用价值。

Prostate cancer (PCa) is a heterogeneous disease with highly variable outcomes. The management of intermediate risk prostate cancer is one of the research hotspots. In our previous study, by using open access prostate cancer expression data, we screened differential expressed genes between Gleason score 3 to 4. After external calibration of prognostic data and validation, we developed a multiple gene signature to distinguish the risk of aggressive/non-aggressive prostate cancer of intermediate risk. Further Gene ontology (GO) study found that these genes were associated with tumor proliferation. We hypothesis that these genes involve in the malignant progression of intermediate risk prostate cancer. This project aims to reveal the mechanism of the gene sets in intermediate risk PCa aggressiveness in vitro and in vivo and find the key genes and signal pathway. In this project, we will build a gene signature for management of intermediate risk PCa which is meaningful for understanding the aggressiveness of the disease and guiding the individualized management of intermediate risk PCa. The project may shed light on early intervention of PCa with important scientific interest and clinical application.